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A B S T R A C T
BACKGROUND AND PURPOSE: Microembolic signals (MES) are detectable by transcranial Doppler monitoring and associated
with increased risk of first or recurrent ischemic stroke. MES detection can also illuminate stroke etiology and the effect of
prophylactic treatment. MES detection cannot accurately distinguish between stroke-related microemboli and ultrasound contrast
agents. These agents contain microbubbles and are frequently used in neuro- and cardiovascular diagnostics. We aimed to assess
how long after contrast infusion microbubbles are detectable by transcranial Doppler monitoring.
METHODS: Ten healthy volunteers received an intravenous infusion of stabilized sulfur hexafluoride microbubbles (SonoVue R©)
for 30 minutes. The infusion was followed by continuous unilateral Doppler monitoring (TCD-X, Atys Medical, Soucieu-en-Jarrest,
France) for 3.5 hours.
RESULTS: MES persisted for 12 to 77 minutes (median 40.5 minutes), and the frequency tended to decrease gradually until
cessation.
CONCLUSIONS: None of the subjects had detectable MES for more than 77 minutes after ultrasound contrast infusion. MES
detection with the intent to detect stroke-related microemboli should wait for at least this long after completed infusion.
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Cerebral microemboli are clinically silent but detectable by
transcranial Doppler monitoring as high-intensity transient sig-
nals. The presence of microembolic signals (MES) is an inde-
pendent risk factor for future ischemic stroke in large-vessel
atherosclerosis and a frequent finding in other embolic causes
of stroke.1–6 MES detection can be used to clarify the cause of
stroke, discover circulating emboli in the acute phase of stroke
or during interventions, and assess the effect of antithrombotic
treatment.7–12
MES detection cannot precisely differentiate between
stroke-related microemboli and ultrasound contrast agents
(UCAs) containing microbubbles.13 These agents enhance
2-dimensional B-mode images and flow-mediated Doppler
signals, providing the opportunity of detailed morpholog-
ical and quantitative information.14 UCAs are potentially
necessary for about 20% of transcranial Doppler exam-
inations due to poor insonation.15 Stabilized sulfur hex-
afluoride (SF6) microbubbles are a frequently used UCA
in neuro- and cardiovascular diagnostics.15,16 It has also
been used in contrast-enhanced sonothrombolysis in acute
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ischemic stroke.17–19 SF6 is administered intravenously and
provides a clinically useful Doppler signal enhancement for
2-9 minutes. The elimination half-life is approximately 6 min-
utes, and more than 80% of the administered SF6 is ex-
haled after 11 minutes. The elimination of SF6 is entirely
pulmonary.20,21
Contrast enhancement is not necessary for MES detection,
but it may be required for vascular examinations that are rele-
vant in stroke diagnostics. If MES detection is performed after
these examinations, it is important to know how long MES
persist after UCA infusion, to avoid confusing microbubbles
and stroke-related microemboli. Although the Doppler signal
enhancement ceases minutes after completed UCA infusion,
we have observed that MES may persist for a longer time. To
our knowledge, the persistence of MES after SF6 infusion has
not previously been investigated. An ambulatory transcranial
Doppler system allows for continuous monitoring for up to sev-
eral hours with minimal discomfort.22,23 We aimed to assess the
persistence of MES after UCA infusion to determine how soon
after infusion, it is feasible to search for microemboli in stroke
diagnostics.
◦C 2019 The Authors. Journal of Neuroimaging published by Wiley Periodicals, Inc. on behalf of
American Society of Neuroimaging
1
Methods
We recruited healthy volunteers as subjects to limit the risk of
stroke-related MES confounding the results. Ten research group
members (60% females, age range 25-71, no history of arterial
disease) received a 30-minute intravenous infusion of SF6 mi-
crobubbles (10 mL SonoVue R© 8 microliters/mL) via a VueJect
infusion pump (Bracco Imaging, Milan, Italy). Continuous infu-
sion was chosen because it is the preferred way of administering
SF6 for neurovascular examinations in our department. Com-
pared to bolus injection, it provides a constant level of con-
trast enhancement with less initial blooming artifacts and an
extended diagnostic window.15,24 In addition, contrast-induced
variations in velocity measurements are reduced.25 Continu-
ous infusion is also the preferred method of administration for
contrast-enhanced sonothrombolysis.19 After completed infu-
sion, the subjects underwent continuous ambulatory Doppler
monitoring for 3.5 hours. The left middle cerebral artery was in-
sonated through the temporal bone window at a depth between
47 and 55 mm with a transcranial robotized 1.5 MHz Doppler
probe (TCD-X, Atys Medical, Soucieu-en-Jarrest, France). Fast
Fourier transform (FFT) settings were, as recommended by the
manufacturer, 128-point FFT with Blackman filter and sample
frequency of 400 Hz. The detection threshold was set to 9 dB,
high-pass filter at 150 Hz, sample volume at 9.9 mm, and gain
at the lowest level that preserved a flow signal in the spec-
trogram. The software algorithms applied for MES detection
and artifact rejection are previously described.26,27 MES were
automatically registered and subsequently verified by three ex-
perienced observers in consensus. MES criteria were defined
by the International Consensus Committee, ie, unidirectional
signals lasting less than 300 milliseconds, with an amplitude at
least 3 dB above the background blood flow intensity and ac-
companied by a characteristic “snap,” “chirp,” or “moan” on
the audible output.28,29 Predisposing conditions potentially re-
lated to interpersonal variations in MES persistence, such as
patent foramen ovale (PFO) or pulmonary shunts, were not
investigated in this study.
MES persistence, defined as the time between completed
UCA infusion and the last detected MES, was presented as me-
dian (interquartile range). Statistical analyses were performed
using STATA 15.1 (StataCorp, College Station, TX, USA). As
the study design was descriptive, power calculations were not
performed.
The study received prior approval by the regional lo-
cal ethics committee (REK Vest) as a substudy of NOR-
MASS (The Norwegian Microemboli in Acute Stroke Study,
Clinical.Trials.gov-ID NCT03543319). Informed consent was
obtained from all individual participants included in the study.
The study was carried out in accordance with the declaration
of Helsinki.
Results
Median MES persistence after SF6 infusion was 40.5 min-
utes (minimum 12 minutes, maximum 77 minutes, interquartile
range 16-51 minutes). Individual MES persistence is presented
in Table 1, and the temporal distribution is shown in Figure 1.
In 9 of 10 subjects, MES ceased after less than 1 hour, and we
observed a gradual decrease in frequency until cessation. In one
subject, we observed a cessation of MES, followed by a second,
spontaneous increase. Emboli detection was performed for 3.5
Table 1. Persistence of Microembolic Signals after Sulfur Hexafluoride
Infusion











MM = minutes; SS = seconds.
hours after complete infusion in all 10 subjects. None of the
subjects had detectable MES after 77 minutes, and all 10 mon-
itoring sequences thereby contain at least 2 hours of MES-free
data after MES cessation. There were no adverse events during
any of the monitoring sequences.
Discussion
This study shows that after UCA infusion, MES persist for a
longer time than the observable Doppler signal enhancement.
In our study sample, none of the subjects had detectable MES
for more than 77 minutes after completed infusion. The search
for stroke-related microemboli should therefore wait for at least
this long. We are not aware of previous studies assessing the
persistence of MES after UCA infusion, and we thereby have
no basis for result comparison.
Figure 1 shows a gradual increase in recorded MES during
the first 5 minutes. This gradual increase does not reflect the
actual temporal distribution of MES. The actual MES frequency
is at its peak during and right after infusion, which can be seen
as a continuous shower of emboli in the spectrogram. The MES
detection software is, however, not able to register all MES
during a shower of emboli, which leads to underestimating of
MES during the first 5 minutes.
This study is novel, it increases our understanding of UCAs,
and it has potential clinical implications for stroke diagnostics
and treatment. Presence of MES in stroke patients implies an
embolic stroke etiology, and cessation of MES may suggest
effect of antithrombotic treatment. This effect can be seen as
early as during the first hour.30 Confusing microbubbles and
stroke-related microemboli may mislead diagnostics and treat-
ment choices. Knowledge of the persistence of MES after UCA
infusion is therefore important.
However, this study also has limitations. The sample size is
small, and the subjects are healthy volunteers. We chose not to
include patients admitted to our stroke unit in the study, as these
are more likely to have stroke-related microemboli, which are
not possible to differentiate from MES caused by microbubbles.
Published data on the pharmacokinetics of SF6 in patients with
organ dysfunction are limited, but rapid, pulmonary elimina-
tion in healthy volunteers suggests a similar rate of elimination
in such patients.31 Still, the presence of a right-to-left shunt (for
example, a PFO) could decrease the elimination of SF6, as this
elimination is entirely pulmonary. PFO has a prevalence of
about 25% in the general population, and it is possible that the
presence of an asymptomatic right-to-left shunt in some of our
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Fig 1. Time distribution of microembolic signals after sulfur hexafluoride infusion.
subjects can explain some of the variations in MES persistence.
This could explain the second increase in MES frequency ob-
served in one of the subjects, but this matter was not further
investigated.
Technical factors in MES detection influence the results
and need consideration. Ultrasound waves cause forced ex-
pansion and compression of microbubbles, leading to bubble
disruption.32 It is thus possible that the MES persistence would
be longer without continuous ultrasound insonation. This influ-
ence is, however, unavoidable, as ultrasound is the only way
of monitoring circulating microbubbles in vivo. MES detection
is dependent on the ultrasound transmission frequency, and
our results with a 1.5 MHz probe may not be comparable to
other clinically used frequencies of 1 or 2 MHz.33 However,
1.5 MHz is currently the only available frequency for an ambu-
latory Doppler system, which was considered necessary when
performing a study with several hours of transcranial monitor-
ing.
The interpretation of the data from the MES detection soft-
ware is challenging. Despite recent advances in automatic em-
bolus detection, human experts are still considered the gold
standard for MES detection.34,35 Assessment by one individual
expert would limit the reproducibility of the result, but we ad-
dressed this by requiring consensus between three experienced
observers.
This study provides new knowledge of microbubble behav-
ior and MES persistence after SF6 infusion. UCAs are fre-
quently used to improve vascular diagnostics in stroke patients,
and MES detection is a pathophysiological adjunct to vascular
imaging. A better understanding of the persistence of MES af-
ter UCA infusion may avoid misinterpreting microbubbles as
stroke-related emboli, which may lead to improved diagnostics
and treatment of stroke patients.
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